Summary

Anti-Obesity Drugs Market Research Report by Treatment Type [Appetite Suppressants (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine Dopamine Reuptake Inhibitors), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others], by Drug Type (Prescription Drugs, Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs, Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Market Overview
The market for anti-obesity drugs is forecast to rise from USD 27.1623 billion in 2024 to USD 326.8969 billion in 2035, advancing at a CAGR of 25.82% between 2025 and 2035. Anti-obesity drugs are therapeutic agents developed to treat obesity and its related complications. By targeting specific biological processes, they help control food intake, improve metabolism, and promote weight reduction. These treatments are most effective when combined with healthy eating habits and regular physical activity.
The worldwide obesity medication anti-obesity drug market is expanding as obesity becomes a serious health problem globally. The development of more inactive lifestyles, high-calorie diets, and environmental elements has resulted in a large number of overweight and obese people.
WHO estimates that more than 800 million people are overweight, and the trend continues to move upwards in both developed and developing countries. Over 30% of adults are obese in high-income areas such as North America and Europe, whereas the numbers are going up rapidly in Asia and Africa. This escalating burden has invigorated the need for the right pharmaceutical solutions treating obesity has contributed to a major event that the FDA approved Zepbound and the India launch of Mounjaro were significant welcome marks.
Public health programs, sugar taxes, and quicker drug approvals are some of the methods by which governments are supporting the fight against obesity. Nevertheless, a great deal of anxiety over the security of drugs, side effects, and long-term health permeates resistance to the adoption of the drugs on a large scale.
The door is open to non-surgical therapies where GLP-1 and dual receptor medications, like those of Eli Lilly and Novo Nordisk, present remarkable results in weight loss. If the trend of obesity resulting in a rise in healthcare and its related costs, which have been estimated to exceed $18 trillion annually by 2060, continues, the market will be gradually growing as it will be supported by R&D investments, patient awareness, and the effort for safer and more effective therapies.

Market Segmentations
The global anti-obesity drugs market is segmented by the treatment type, comprising appetite suppressants, lipase inhibitors, GLP-1 receptor agonists, combination drugs, and others. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.
Based on the drug type, the global market is classified into prescription drugs and over-the-counter drugs.
Centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs are part of the mechanism of action of the global anti-obesity drugs market.
Depending on the route of administration, the global market is divided into oral and subcutaneous.
Hospital, retail, and online pharmacies are the distribution channel category of the global market.

Regional Insights
Obesity has been a double-edged sword for North America, the prevalence of which has been its market's economic power. The social and economic damage caused by obesity in the U.S. is rapidly transforming the political landscape so that authorities are eager to promote drug use alongside lifestyle interventions. An aging population with multiple health issues is driving up the demand for medical weight management. Moreover, employers are also pouring money into health insurance plans that include obesity drugs with an aim to long-term healthcare expenditure cut. The regional economic logic is enticing for pharma to keep investing here.
The aging society in Europe has been the source of healthcare costs in the region, but the eventual effect of this has been the increased demand for preventive obesity treatments. Obesity drugs are much more accessible under universal healthcare in most EU countries; however, budget restrictions are still the key factor in the decision for the so-called cost-effectiveness studies that will be used to prove the extensive adoption of them. Most of the demand comes from countries with the highest number of obese people in the region, i.e., those in Eastern and Southern Europe. Harmonization of policies in the EU has made it possible for drugs that are approved to enter several markets quickly. Furthermore, the economic gap between Western and Eastern Europe is influencing the way products are priced.
Asia-Pacific's prosperity is the root cause of various lifestyle changes, most of which increase the risk of obesity, particularly in the area's rapidly growing urban centers. The growing middle class in China, India, and Southeast Asia is making it possible for more people to access prescription medications. With the younger demographics showing interest in medical weight loss, they are gradually shifting away from the traditional methods. Furthermore, corporate wellness programs are also beginning to include obesity drugs in the list of employee health benefits. The economic progress is also allowing governments to step in and provide subsidies for treatment for the high-risk groups.
Positive economic developments in South America have opened the door to better healthcare, which has led to a rise in the use of anti-obesity drugs in the urban middle class. The association of obesity with lowered productivity of employed individuals has led to the concept of obesity as a latent economic burden. In Brazil, the government health care system is piloting various insurance coverage plans for obesity medicines. It appears that governments are channeling funds into health promotion campaigns with the goal of ensuring that patients take their prescriptions on time. Drug makers are crafting pricing plans that are more attractive to the budget-savvy buyers to facilitate sales.
In the Middle East & Africa, economic development and urban expansion are driving lifestyle changes that contribute to obesity. Wealthier Gulf nations are leading in drug adoption, while African uptake is concentrated in countries with growing private healthcare sectors. Government health budgets are increasingly allocating funds to chronic disease prevention, including obesity. Young, urban populations are becoming more health-conscious, fueling interest in prescription weight-loss treatments. Price sensitivity remains a factor, making tiered pricing strategies important for market growth.

Major Players
Key players in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION ............ 22
2.1 DEFINITION .. 22
2.2 SCOPE OF THE STUDY .............. 22
2.3 RESEARCH OBJECTIVE ............ 22
2.4 MARKET STRUCTURE .............. 23
3 RESEARCH METHODOLOGY ...... 24
3.1 OVERVIEW .... 24
3.2 DATA FLOW .. 26
3.2.1 DATA MINING PROCESS ................. 26
3.3 PURCHASED DATABASE: ......... 27
3.4 SECONDARY SOURCES: ............ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: ............. 29
3.5 PRIMARY RESEARCH: ............... 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ................. 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......... 32
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .. 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........... 33
3.6.1 REVENUE ANALYSIS APPROACH ..... 33
3.7 DATA FORECASTING................. 34
3.7.1 DATA FORECASTING TYPE .............. 34
3.8 DATA MODELING ........ 35
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............ 35
3.8.2 DATA MODELING: ........... 36
3.9 TEAMS AND ANALYST CONTRIBUTION ........... 38
4 MARKET DYNAMICS .... 40
4.1 INTRODUCTION ........... 40
4.2 DRIVERS ......... 40
4.2.1 RISING PREVALENCE OF OBESITY ... 40
4.2.2 INCREASING GOVERNMENT INITIATIVES AND SUPPORT .. 41
4.3 RESTRAINTS ................ 42
4.3.1 SIDE EFFECTS AND SAFETY CONCERNS .......... 42
4.4 OPPORTUNITY ............. 43
4.4.1 FOCUS ON NON-SURGICAL OBESITY TREATMENTS .......... 43
5 MARKET FACTOR ANALYSIS ...... 44
5.1 PORTER'S FIVE FORCES MODEL ........... 44
5.1.1 THREAT OF NEW ENTRANTS ........... 44
5.1.2 BARGAINING POWER OF SUPPLIERS ............... 45
5.1.3 THREAT OF SUBSTITUTES .............. 45
5.1.4 BARGAINING POWER OF BUYERS .... 45
5.1.5 INTENSITY OF RIVALRY .. 45
5.2 IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET ...... 45
5.3 MARKET TRENDS ...... 46
5.4 REGULATORY LANDSCAPE .... 47
5.4.1 NORTH AMERICA ............ 47
5.4.2 EUROPE ......... 47
5.4.3 ASIA-PACIFIC ................. 47
5.4.4 LATIN AMERICA ............. 48
5.4.5 MIDDLE EAST AND AFRICA ............. 48
5.5 UNMET NEEDS ............ 48
5.6 EPIDEMIOLOGY ASSESSMENT .............. 50
5.7 BRAND AND PIPELINE ANALYSIS ....... 52
5.8 PRICING ANALYSIS.... 53
6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE .......... 55
6.1 OVERVIEW .... 55
6.1 APPETITE SUPPRESSANTS .... 58
6.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS ... 59
6.1.2 SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS ........... 60
6.1.3 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS) ........ 60
6.2 LIPASE INHIBITORS ... 61
6.3 GLP-1 RECEPTOR AGONISTS ... 61
6.4 COMBINATION DRUGS .............. 62
6.5 OTHERS .......... 62
7 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE ..... 63
7.1 OVERVIEW .... 63
7.2 PRESCRIPTION DRUGS ............. 65
7.3 OVER THE COUNTER DRUGS .. 65
8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION ................ 66
8.1 OVERVIEW .... 66
8.2 CENTRALLY ACTING ANTI-OBESITY DRUGS .. 68
8.3 PERIPHERALLY ACTING ANTI-OBESITY DRUGS ............ 68
9 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION ........ 69
9.1 OVERVIEW .... 69
9.2 ORAL ............... 70
9.3 SUBCUTANEOUS ........ 71
10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL ............... 72
10.1 OVERVIEW .... 72
10.2 HOSPITAL PHARMACIES ......... 74
10.3 RETAIL PHARMACIES .............. 74
10.4 ONLINE PHARMACIES .............. 75
11 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION ............ 76
11.1 OVERVIEW .... 76
11.2 NORTH AMERICA ....... 77
11.2.1 US.. 81
11.2.2 CANADA ........ 83
11.3 EUROPE .......... 85
11.3.1 GERMANY ...... 89
11.3.2 FRANCE ......... 91
11.3.3 UK ................. 94
11.3.4 SPAIN ............ 96
11.3.5 ITALY ............. 98
11.3.6 RUSSIA .......... 99
11.3.7 REST OF EUROPE ............ 101
11.4 ASIA PACIFIC ............... 105
11.4.1 CHINA ............ 109
11.4.2 INDIA ............. 111
11.4.3 JAPAN ........... 113
11.4.4 SOUTH KOREA ................ 115
11.4.5 MALAYSIA ..... 117
11.4.6 THAILAND ...... 119
11.4.7 INDONESIA ..... 121
11.4.8 REST OF ASIA PACIFIC.... 123
11.5 SOUTH AMERICA ....... 126
11.5.1 BRAZIL ........... 129
11.5.2 MEXICO ......... 132
11.5.3 ARGENTINA ... 134
11.5.4 REST OF SOUTH AMERICA .............. 136
11.6 MIDDLE EAST AND AFRICA .... 139
11.6.1 GCC COUNTRIES............. 143
11.6.2 SOUTH AFRICA ............... 145
11.6.3 REST OF MEA ................. 147
12 COMPETITIVE LANDSCAPE ........ 151
12.1 INTRODUCTION ........... 151
12.2 MARKET SHARE ANALYSIS, 2024 ....... 151
12.3 COMPETITOR DASHBOARD..... 152
12.4 PUBLIC PLAYERS STOCK SUMMARY ................. 153
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL .............. 153
12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ............ 154
12.1.1 PRODUCT APPROVAL ..... 154
12.1.2 MARKETING APPROVAL ................. 154
12.1.3 PRODUCT EXPANSION .... 155
12.1.4 FACILITY LAUNCH .......... 155
12.1.5 AQUISITION .... 155
12.1.6 AGREEMENT .. 156
13 COMPANY PROFILES .. 157
13.1 ELI LILLY AND COMPANY ....... 157
13.1.1 COMPANY OVERVIEW ..... 157
13.1.2 FINANCIAL OVERVIEW .... 158
13.1.3 PRODUCTS OFFERED ...... 159
13.1.4 KEY DEVELOPMENTS ...... 159
13.1.5 SWOT ANALYSIS ............ 160
13.1.6 KEY STRATEGIES ............ 160
13.2 ASTRAZENECA............ 161
13.2.1 COMPANY OVERVIEW ..... 161
13.2.2 FINANCIAL OVERVIEW .... 162
13.2.3 PRODUCTS OFFERED ...... 162
13.2.4 KEY DEVELOPMENTS ...... 163
13.2.5 SWOT ANALYSIS ............ 163
13.2.6 KEY STRATEGIES ............ 163
13.3 GSK PLC .......... 164
13.3.1 COMPANY OVERVIEW ..... 164
13.3.2 FINANCIAL OVERVIEW .... 165
13.3.3 PRODUCT OFFERED ........ 165
13.3.4 KEY DEVELOPMENTS ...... 166
13.3.5 SWOT ANALYSIS ............ 166
13.3.6 KEY STRATEGIES ............ 166
13.4 GELESIS .......... 167
13.4.1 COMPANY OVERVIEW ..... 167
13.4.2 FINANCIAL OVERVIEW .... 167
13.4.3 PRODUCTS OFFERED ...... 167
13.4.4 KEY DEVELOPMENTS ...... 167
13.4.5 KEY STRATEGIES ............ 168
13.5 CHEPLAPHARM ARZNEIMITTEL GMBH ........... 169
13.5.1 COMPANY OVERVIEW ..... 169
13.5.2 FINANCIAL OVERVIEW .... 170
13.5.3 PRODUCT OFFERED ........ 170
13.5.4 KEY DEVELOPMENTS ...... 170
13.5.5 KEY STRATEGIES ............ 170
13.6 NOVO NORDISK A/S ... 171
13.6.1 COMPANY OVERVIEW ..... 171
13.6.2 FINANCIAL OVERVIEW .... 172
13.6.3 PRODUCTS OFFERED ...... 173
13.6.4 KEY DEVELOPMENTS ...... 173
13.6.5 SWOT ANALYSIS ............ 173
13.6.6 KEY STRATEGIES ............ 174
13.7 RHYTHM PHARMACEUTICALS, INC. .. 175
13.7.1 COMPANY OVERVIEW ..... 175
13.7.2 FINANCIAL OVERVIEW .... 176
13.7.3 PRODUCTS OFFERED ...... 176
13.7.4 KEY DEVELOPMENTS ...... 177
13.7.5 SWOT ANALYSIS ............ 178
13.7.6 KEY STRATEGIES ............ 178
13.8 KVK TECH, INC. ........... 179
13.8.1 COMPANY OVERVIEW ..... 179
13.8.2 FINANCIAL OVERVIEW .... 179
13.8.3 PRODUCTS OFFERED ...... 180
13.8.4 KEY DEVELOPMENTS ...... 180
13.8.5 KEY STRATEGIES ............ 180
13.9 CURRAX PHARMACEUTICALS LLC ..... 181
13.9.1 COMPANY OVERVIEW ..... 181
13.9.2 FINANCIAL OVERVIEW .... 181
13.9.3 PRODUCTS OFFERED ...... 182
13.9.4 KEY DEVELOPMENTS ...... 182
13.9.5 KEY STRATEGIES ............ 182
13.10 VIVUS LLC ..... 183
13.10.1 COMPANY OVERVIEW ..... 183
13.10.2 FINANCIAL OVERVIEW .... 183
13.10.3 PRODUCTS OFFERED ...... 183
13.10.4 KEY DEVELOPMENTS ...... 184
13.10.5 KEY STRATEGIES ............ 184
14 DATA CITATIONS ......... 185